Literature DB >> 7674386

Limiting initial resuscitation of uncontrolled hemorrhage reduces internal bleeding and subsequent volume requirements.

T M Owens1, W C Watson, D S Prough, T Uchida, G C Kramer.   

Abstract

We tested the hypothesis that full or "standard resuscitation" (SR) with lactated Ringer's solution (LRS) results in increased bleeding in uncontrolled hemorrhagic shock, compared with a "limited prehospital resuscitation" (LPR) regimen and a control group of "no resuscitation" (NR). Cardiac output was used as physiological endpoint for resuscitation. Twenty swine had 25 mL/kg of blood withdrawn during a 30-minute controlled hemorrhage, followed by a 20-minute "prehospital" resuscitation regimen was conducted in three groups: the SR group (n = 6), LRS infused as needed to restore cardiac index (CI) to 100% baseline; the LPR group (n = 8), with resuscitation using LRS to 60% of baseline CI, with volume limited to 10 mL/kg; and the NR group (n = 6). After aortotomy repair, intraoperative resuscitation was continued for 120 minutes using LRS to achieve and maintain 80% of baseline mean arterial pressure. Blood pressure and cardiac index were greatly reduced, to 34% and 39% of baseline, respectively, by hemorrhage. During prehospital resuscitation, the SR group required 48.8 +/- 6.5 mL/kg of LRS, whereas the LPR group received 9.4 +/- 0.6 mL/kg (p < 0.05). Mean arterial pressure increased in all three groups during prehospital resuscitation (p < 0.05). Pulse pressures increased in the SR and LPR groups only (p < 0.05). The increment in oxygen delivery was significantly greater in the SR group, compared with the LPR group (p < 0.05), which in turn was significantly greater than the NR group (p < 0.05). Peritoneal blood volume was significantly higher in the SR group (20.6 +/- 5.6 mL/kg), versus the LPR (7.3 +/- 1.3 mL/kg; p < 0.05) and NR groups (3.0 +/- 0.9 mL/kg; p < 0.05). Crystalloid and whole blood requirements during the intraoperative resuscitation phase were significantly higher in the SR group (193 +/- 16.0 and 9.0 +/- 2.5 mL/kg), than in LPR (111.8 +/- 15.6 and 4.5 +/- 1.8 mL/kg; p < 0.05) and NR groups (128.5 +/- 32.3 and 3.9 +/- 2.3 mL/kg; p < 0.05). In the presence of uncontrolled hemorrhagic shock, LPR and NR can significantly reduce internal hemorrhage and subsequent intraoperative crystalloid and blood requirements.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7674386     DOI: 10.1097/00005373-199508000-00004

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  5 in total

1.  Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock.

Authors:  Carlos A Macias; Jeffrey W Chiao; Jingbo Xiao; Devinder S Arora; Yulia Y Tyurina; Russell L Delude; Peter Wipf; Valerian E Kagan; Mitchell P Fink
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Hypotensive Resuscitation.

Authors:  Jeremy B Smith; Jean-Francois Pittet; Albert Pierce
Journal:  Curr Anesthesiol Rep       Date:  2014-09-01

3.  Effects of fibrinogen concentrate after shock/resuscitation: a comparison between in vivo microvascular clot formation and thromboelastometry*.

Authors:  Judith Martini; Pedro Cabrales; Dietmar Fries; Marcos Intaglietta; Amy G Tsai
Journal:  Crit Care Med       Date:  2013-11       Impact factor: 7.598

4.  p-Hydroxyphenylpyruvate, an intermediate of the Phe/Tyr catabolism, improves mitochondrial oxidative metabolism under stressing conditions and prolongs survival in rats subjected to profound hemorrhagic shock.

Authors:  Antonella Cotoia; Rosella Scrima; Julia V Gefter; Claudia Piccoli; Gilda Cinnella; Michele Dambrosio; Mitchell P Fink; Nazzareno Capitanio
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

Review 5.  The clinical effectiveness of permissive hypotension in blunt abdominal trauma with hemorrhagic shock but without head or spine injuries or burns: a systematic review.

Authors:  Abdulrahman Alsawadi
Journal:  Open Access Emerg Med       Date:  2012-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.